Cited by 187Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatmentsMedicinal Plants and Neuroprotection

Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer’s disease

Open access
Jabir, Nasimudeen R., Khan, Fayaz Rahman, Tabrez, Shams·2018·CNS Neuroscience & Therapeutics

Abstract

Alzheimer's disease (AD) is a progressive irreversible neurodegenerative disorder characterized by excessive deposition of β-amyloid (Aβ) oligomers, and neurofibrillary tangles (NFTs), comprising of hyperphosphorylated tau proteins. The cholinergic system has been suggested as the earliest and most affected molecular mechanism that describes AD pathophysiology. Moreover, cholinesterase inhibitors (ChEIs) are the potential class of drugs that can amplify cholinergic activity to improve cognition and global performance and reduce psychiatric and behavioral disturbances. Approximately, 60%-80% of all cases of dementia in the world are patients with AD. In view of the continuous rise of this disease especially in the aged population, there is a dire need to come up with a novel compound and/or mixture that could work against this devastating disease. In this regard, the best is to rely on natural compounds rather than synthetic ones, because natural compounds are easily available, cost-effective, and comparatively less toxic. To serve this purpose, lately, scientific community has started exploring the possibility of using different polyphenols either solitary or in combination that can serve as therapeutics against AD. In the current article, we have summarized the role of various polyphenols, namely quercetin, resveratrol, curcumin, gallocatechins, cinnamic acid, caffeine, and caffeic acid as an inhibitor of cholinesterase for the treatment of AD. We have also tried to uncover the mechanistic insight on the action of these polyphenols against AD pathogenicity.

Integrity signals

Registry

Crossref · 10.1111/cns.12971

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Plant extracts may serve as valuable adjuncts or alternatives to conventional pharmacological treatments for Alzheimer's disease.

    “The diverse mechanisms through which these plant extracts exert their effects—ranging from ChE inhibition to antioxidant activity—suggested that they may serve as valuable adjuncts or alternatives to conventional pharmacological treatments for AD [103,104].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jabir, N. R., Khan, F. R., & Tabrez, S.
Affiliations
King Abdulaziz University (SA)
Corresponding author
Tabrez, Shams
Venue
CNS Neuroscience & Therapeutics
Publisher
Wiley
Published
2018-05-16
Volume
24
Issue
9
Pages
753-762
ISSN
  • 1755-5930 (ISSN-L)
  • 1755-5949
OpenAlex
W2803878064
Cited by
187
References
111
Citations by year
2026: 13 · 2025: 28 · 2024: 25 · 2023: 21 · 2022: 33 · 2021: 34 · 2020: 15 · 2019: 14 · 2018: 2 · 2017: 1
FWCI
1.90
Type
journal article
Language
en
Open access
Locations
  • CNS Neuroscience & Therapeutics (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
Keywords
Alzheimer's disease, cholinesterase inhibitors, polyphenols, cholinergic system, quercetin, resveratrol, curcumin, gallocatechin, cinnamic acid, caffeine, caffeic acid, natural compounds, amyloid-beta, tau hyperphosphorylation, neurofibrillary tangles, neurodegeneration
MeSH terms
Alzheimer Disease, Animals, Cholinesterase Inhibitors, Cholinesterases, Humans, Drug Delivery Systems, tau Proteins, Treatment Outcome, Polyphenols

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review